Celsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update
November 14, 2019 16:05 ET
|
Celsion CORP
Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy AnalysisIndependent Data Safety Monitoring Board (DSMB)...
Celsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update
August 14, 2019 16:30 ET
|
Celsion CORP
First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New Jersey State Net Operating...
Celsion's GEN-1 Immunotherapy Highlighted in Oppenheimer's Expert Call on Ovarian Cancer Treatment Landscape and Emerging Opportunities
August 09, 2019 08:30 ET
|
Celsion CORP
Presentation Slides Available on Celsion’s Website LAWRENCEVILLE, N.J, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug-development company, announces that...
Celsion Corporation Reports First Quarter 2019 Financial Results and Provides Business Update
May 15, 2019 08:00 ET
|
Celsion CORP
Company to Hold Conference Call on Wednesday, May 15, 2019 at 11:00 a.m. EDT LAWRENCEVILLE, N.J, May 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug...
Celsion Corporation to Hold First Quarter 2019 Financial Results Conference Call on Wednesday, May 15, 2019
May 08, 2019 17:00 ET
|
Celsion CORP
LAWRENCEVILLE, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the quarter...
Celsion Corporation Reports 2018 Financial Results
March 29, 2019 08:00 ET
|
Celsion CORP
Celsion Enters 2019 with a Strong Balance Sheet, Clean Capitalization Structure and an Advancing Clinical Pipeline Company to Hold Conference Call on Friday, March 29, 2019 at 11:00 a.m. EDT ...
Celsion Corporation to Hold Year-End 2018 Financial Results Conference Call on Friday, March 29, 2019
March 22, 2019 08:30 ET
|
Celsion CORP
LAWRENCEVILLE, N.J, March 22, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the year ended...
Celsion Announces Presentation of GEN-1 Data at Upcoming ASCO-SITC Clinical Immuno-Oncology Symposium
January 15, 2019 08:30 ET
|
Celsion CORP
Data to be Highlighted During Oral Session on March 2, 2019 LAWRENCEVILLE, N.J., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today...
Celsion Receives $11.1 Million Allocation Through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program
December 03, 2018 09:15 ET
|
Celsion CORP
Non-Dilutive Funding Strengthens Balance Sheet Proceeds Equate to More Than $0.55 Per Share LAWRENCEVILLE, N.J., Dec. 03, 2018 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an...
Celsion Announces Publication Highlighting the Potential of Celsion's Gene-Mediated Immunotherapy to Improve Administration of IL-12 and Progression-Free Survival in Ovarian Cancer Patients
October 22, 2018 09:20 ET
|
Celsion CORP
Analysis in peer-reviewed journal, Future Oncology, outlines the ability of GEN-1, a non-viral nanoparticle delivery system, to support persistent local production of IL-12 LAWRENCEVILLE, N.J,...